In one study (Carey et al, 2007), the basal-like and HER2 subtypes, defined by hormone receptor IHC only, had the highest rates of pCR to pre-operative anthracycline-based chemotherapy, whereas the luminal tumours responded poorly. This evidence concerns the gene ERBB2 and neoplasm.